Biogen Avonex Defense: Seek Broader Label, Boost Promo/Patient Efforts
Executive Summary
Biogen's plan to defend Avonex from Serono's entry with Rebif includes pursuing a broader multiple sclerosis label while enhancing marketing and patient retention efforts to protect current usage
You may also be interested in...
Avonex “Dear Doctor” Letter Updates Safety; New Indication For Early MS
Biogen will issue a "Dear Doctor" letter by March 16 to inform physicians of updated safety information for its multiple sclerosis agent Avonex
Avonex “Dear Doctor” Letter Updates Safety; New Indication For Early MS
Biogen will issue a "Dear Doctor" letter by March 16 to inform physicians of updated safety information for its multiple sclerosis agent Avonex
Serono Rebif 25% Market Share Expected By 2006; Monthly Price Is $1,156
Serono hopes Rebif will capture a quarter of the multiple sclerosis market by 2006, CEO Ernesto Bertarelli told securities analysts during a March 11 conference call